Paul Secrist

2021

In 2021, Paul Secrist earned a total compensation of $1.1M as Chief Scientific Officer at Cyteir Therapeutics, a 113% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$149,916
Option Awards$556,815
Salary$385,105
Total$1,091,836

Secrist received $556.8K in option awards, accounting for 51% of the total pay in 2021.

Secrist also received $149.9K in non-equity incentive plan and $385.1K in salary.

Rankings

In 2021, Paul Secrist's compensation ranked 8,491st out of 12,415 executives tracked by ExecPay. In other words, Secrist earned more than 31.6% of executives.

ClassificationRankingPercentile
All
8,491
out of 12,415
32nd
Division
Manufacturing
3,764
out of 5,505
32nd
Major group
Chemicals And Allied Products
1,668
out of 2,375
30th
Industry group
Drugs
1,485
out of 2,096
29th
Industry
Pharmaceutical Preparations
1,106
out of 1,546
29th
Source: SEC filing on April 29, 2022.

Secrist's colleagues

We found two more compensation records of executives who worked with Paul Secrist at Cyteir Therapeutics in 2021.

2021

Markus Renschler

Cyteir Therapeutics

Chief Executive Officer

2021

Andrew Gengos

Cyteir Therapeutics

Chief Business Officer

News

In-depth

You may also like